Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C21H24ClN2O4S.Na |
| Molecular Weight | 458.934 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CN1C2=C(C=CC=C2)C(NCCCCCCC([O-])=O)C3=CC=C(Cl)C=C3S1(=O)=O
InChI
InChIKey=ZLBSUOGMZDXYKE-UHFFFAOYSA-M
InChI=1S/C21H25ClN2O4S.Na/c1-24-18-9-6-5-8-16(18)21(23-13-7-3-2-4-10-20(25)26)17-12-11-15(22)14-19(17)29(24,27)28;/h5-6,8-9,11-12,14,21,23H,2-4,7,10,13H2,1H3,(H,25,26);/q;+1/p-1
TIANEPTINE, a tricyclic antidepressant, is a drug used for the treatment of the major depressive disorder. It was discovered by The French Society of Medical Research in the 1980s. Unlike other tricyclic antidepressants, TIANEPTINE is a selective serotonin reuptake enhancer with minimal effects on norepinephrine and dopamine uptake. Also, it is a full agonist at the mu-opioid and delta-opioid receptors with no effect at the kappa-opioid receptors. Selective mu-opioid agonists typically induce euphoria, which may contribute to TIANEPTINE's antidepressant effect. It is marketed as Coaxil/Stablon in many European countries, but it is not available in the US.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Structural plasticity and tianeptine: cellular and molecular targets. | 2002 Jul |
|
| Synaptic plasticity and tianeptine: structural regulation. | 2002 Jul |
|
| Effect of antidepressant drugs on the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells. | 2002 Nov-Dec |
|
| [Clinical efficacy and tolerability of tianeptine in treatment of depression (Russian open multicenter trial)]. | 2003 |
|
| [Therapy of affective disorders with tianeptine in patients with essential hypertension]. | 2003 |
|
| Treatment of major depression and anxiety with the selective serotonin re-uptake enhancer tianeptine in the outpatient psychiatric care setting of India. | 2003 Feb |
|
| Effect of antidepressants on the phospholipase A2 activity in plasma membranes of the rat brain cortex. | 2003 Jan-Feb |
|
| Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder. | 2003 Jul |
|
| Antidepressants: psychiatrists' opinions and clinical practice. | 2003 Jul |
|
| [A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression]. | 2003 Jul-Aug |
|
| [Therapy resistant major depression: improvement of symptomatology after combining antidepressants with Tianeptine (Stablon)]. | 2003 May |
|
| Evaluation of cognitive function of fluoxetine, sertraline and tianeptine in isolation and chronic unpredictable mild stress-induced depressive Wistar rats. | 2003 Nov |
|
| [Misuse of tianeptine: five cases of abuse]. | 2003 Nov |
|
| Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation. | 2003 Nov 15 |
|
| Prenatal stress in rats predicts immobility behavior in the forced swim test. Effects of a chronic treatment with tianeptine. | 2003 Nov 7 |
|
| [Does addiction to antidepressants exist? About a case of one addiction to tianeptine]. | 2003 Sep-Oct |
|
| [A role of depression in chronic dorsalgia: approaches to therapeutic correction]. | 2004 |
|
| [Preventive efficacy of tianeptine in recurrent depression with frequent exacerbations]. | 2004 |
|
| Behavioural effects of thieno and pyrazolo [2,1] benzothiazepine derivatives in mice. | 2004 |
|
| Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases. | 2004 |
|
| [Depressions and disorders of depressive spectrum in general medical practice. Results of the COMPAS program]. | 2004 |
|
| Trends in the development of new antidepressants. Is there a light at the end of the tunnel? | 2004 Apr |
|
| Regulation of the human corticotropin-releasing-hormone gene promoter activity by antidepressant drugs in Neuro-2A and AtT-20 cells. | 2004 Apr |
|
| The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. | 2004 Dec |
|
| From restoration of neuroplasticity to the treatment of depression: clinical experience. | 2004 Dec |
|
| Alterations of neuroplasticity in depression: the hippocampus and beyond. | 2004 Dec |
|
| Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. | 2004 Feb |
|
| Reboxetine: a norepinephrine selective reuptake pump inhibitor. | 2004 Jan |
|
| Untreated depression and hippocampal volume loss. | 2004 Jul |
|
| Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. | 2004 Jul |
|
| [Extrapyramidal syndrome worsened by tianeptine]. | 2004 Jul-Aug |
|
| The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. | 2004 Jun 15 |
|
| Refractory pain-depression syndrome treated with tianeptine: a case report. | 2004 Mar |
|
| Treatment of bronchial asthma with tianeptine. | 2004 Nov |
|
| Differential regulation of variant glucocorticoid receptor mRNAs in the rat hippocampus by the antidepressant fluoxetine. | 2004 Oct 22 |
|
| Tianeptine: a facilitator of the reuptake of serotonin and norepinephrine as an antidepressant? | 2004 Sep |
|
| The pharmacological management of depression. | 2005 |
|
| [Depressive disorders in general medical practice in KOMPAS study: outlook of a cardiologist]. | 2005 |
|
| [Coaxil therapy of affective disorders in brain vascular pathology]. | 2005 |
|
| [Coaxil treatment of primary headaches comorbid with depression]. | 2005 |
|
| Treatment of depression with the serotonin reuptake enhancer tianeptine in the primary care setting of India. | 2005 Feb |
|
| [Synaptic plasticity and neuropathology: new approaches in drug discovery]. | 2005 Jan |
|
| [Evaluation of antidepressant activity in a model of depressionlike state due to social isolation in rats]. | 2005 Jul-Aug |
|
| Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. | 2005 Jun |
|
| Social stress in tree shrews as an animal model of depression: an example of a behavioral model of a CNS disorder. | 2005 Mar |
|
| Investigation of the effects of tianeptine and fluoxetine on pentylenetetrazole-induced seizures in rats. | 2005 Mar |
|
| [Comparative study of the antidepressant and anxiolytic activity of fluoxetine and tianeptine]. | 2005 May-Jun |
|
| A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. | 2006 Apr |
|
| Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. | 2006 Feb 1 |
|
| Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. | 2006 Jan 27 |
Patents
Sample Use Guides
Using radioligand binding and cell-based functional assays, including bioluminescence resonance energy transfer-based assays for G-protein activation and cAMP accumulation, tianeptine was identified as an efficacious mu-opioid receptor agonist (Ki of 383+/-183 nM and EC50 of 194+/-70 nM). Tianeptine was also a full delta-opioid receptor agonist, although with much lower potency (EC50 of 37.4+/-11.2 uM for G-protein activation). In contrast, tianeptine was inactive at the kappa-opioid receptor.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ROJ48D5596
Created by
admin on Sat Dec 16 10:25:45 GMT 2023 , Edited by admin on Sat Dec 16 10:25:45 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
